Zealand Pharma A/S (ZLDPY) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 9, 2026 1:20 PM EDT
Company Participants
Adam Steensberg – President & CEO
Conference Call Participants
Rajan Sharma – Goldman Sachs Group, Inc., Research Division
Presentation
Rajan Sharma
Goldman Sachs Group, Inc., Research Division
Good afternoon, everyone. Thanks for joining us. My name is Rajan Sharma, European pharma and biotech analyst here at Goldman Sachs. Very pleased to have Zealand Pharma with us and Adam Steensberg, CEO. Adam, thank you. Thanks for joining. I know that you’ve been on the road with ADA. So thanks for adding on this to the trip.
Adam Steensberg
President & CEO
Pleased to be here.
Question-and-Answer Session
Rajan Sharma
Goldman Sachs Group, Inc., Research Division
Lots to get through. And obviously, we’re coming off the back of ADA. So maybe that’s a good place to start. There are a few updates there, both with survodutide and petrelintide. Could you maybe just start with survodutide because that was kind of the more — or the newer update that we got over the weekend and just provide your thoughts on the data.
Adam Steensberg
President & CEO
Absolutely. And as you said, I just went almost a week around at ADA, and it was really, you can say, positive experience coming out of ADA, kicking off Friday with a symposium on amylin and really starting to change the conversations from how we get to the maximum tolerated doses more towards how do you get to the minimum effective doses when you think about treating obesity.
So there’s a quite significant change in the ecosystem right now that we start to see more modalities approaching the market and specifically with Boehringer being the CEO, Sid, and I was, of course, extremely pleased to see the strong presence they
